DC-ELIQUENT-LIFE-SCIENCE
ELIQUENT Life Sciences, a global regulatory consulting firm for the life sciences industry, today announced the appointment of Steve Purtell as its new chief financial officer (CFO). This strategic addition to ELIQUENT’s executive team underscores the company’s commitment to financial excellence and sustainable growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240111611119/en/
Steve Purtell - Chief Financial Officer, ELIQUENT Life Sciences (Photo: Business Wire)
“Steve’s appointment comes at a pivotal moment for ELIQUENT. As we unify the five Validant Group companies and expand our global footprint, Steve’s leadership and financial expertise will play a critical role in our continued growth,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.
In his role as CFO, Steve is responsible for directing and executing all of ELIQUENT’s finance activities. This includes partnering with the CEO and executive team to ensure the company’s financial direction aligns with the company’s strategic vision and long-term growth objectives. Steve will also serve as a key liaison to investors and the financial community while embedding a strong risk and compliance management framework across ELIQUENT’s growing global market.
A seasoned finance executive with nearly 30 years’ experience, Steve has held key roles at multiple public companies across diverse industries. Steve joined ELIQUENT Life Sciences following more than 10 years at Six Flags, where he served in several finance-related roles, including Interim CFO. As a key advisor to the chief executive officer, Steve was responsible for managing external financial relationships, strategic communications, and mergers and acquisitions for the $1.5 billion entertainment company.
Steve also held leadership roles at Siemens Healthcare, where he served as Vice President of Global Commercial Excellence, Vice President of Finance, and Treasurer of the company’s $25 billion healthcare division. Prior to joining Siemens Healthcare, Steve served in financial roles at Dade Behring, IMC Global, and GATX. Before his corporate career, Steve served as a Combat Engineer Officer in the U.S. Army and was awarded a Bronze Star Medal in the Persian Gulf War.
Steve received a B.S. degree in Civil Engineering from the U. S. Military Academy at West Point and an MBA from the Wharton School.
About ELIQUENT Life Sciences
ELIQUENT Life Sciences is the fusion of five global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, and IDEC. The ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for the products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111611119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC Group and Jefferies Significantly Expand Their Global Strategic Alliance19.9.2025 10:00:00 CEST | Press release
Joint Venture to Combine Equities and ECM Businesses in JapanExpanding Joint Coverage of Larger SponsorsIn EMEA, Implementing Joint Origination, Underwriting and Execution of Syndicated Leveraged Finance for These ClientsSMBC to Increase Equity Ownership in Jefferies to up to 20% in the Open MarketSMBC to Provide Jefferies Approximately $2.5 Billion in New Credit Facilities to Support Jefferies and to Facilitate Collaboration Efforts Jefferies Financial Group, Inc. (NYSE: JEF) (“Jefferies”) and Sumitomo Mitsui Financial Group, Inc. (NYSE: SMFG) (“SMFG”), Sumitomo Mitsui Banking Corporation (“SMBC”), and SMBC Nikko Securities Inc. (“SMBC Nikko”) (collectively, “SMBC Group”) announced today that they are significantly expanding their Global Strategic Alliance. SMBC Group and Jefferies initially entered into a Strategic Alliance in 2021 to collaborate on future corporate and investment banking business opportunities. In 2023, the Alliance was expanded to enhance collaboration across M&A,
REJO MULTI Unveiled at InterTabac 2025, Featuring Dual-Heating and Cross-Brand Compatibility19.9.2025 10:00:00 CEST | Press release
Flexible brand options, enhanced aroma, and reduced tobacco consumption empower REJO's ambition in Europe REJO, a global heat-not-burn (HNB) pioneer, officially unveiled REJO MULTI device at InterTabac 2025 as one of the exhibition’s most anticipated products. The device introduces a dual-heating system that pairs AirFlow and Round Heating technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919713971/en/ REJO MULTI Product Launch Event “REJO MULTI represents a major step forward in HNB technology,” said Loic Li, the Global Sales Director of REJO. “Its open compatibility allows users to explore multiple brands and flavors with a single device, while our dual-heating system ensures even heating, enhanced aroma delivery, and consistent nicotine satisfaction.” “Our goal with REJO MULTI is to empower users with choice and flexibility, while providing retailers and partners with an innovative, market-ready product that
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
Andersen Consulting tilføjer samarbejdsfirmaet Charter18.9.2025 17:14:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine digitale transformationskapaciteter gennem en samarbejdsaftale med Charter, et canadisk konsulentfirma, der er specialiseret i IT-strategi, managed services og applikationslevering. Charter blev grundlagt i 1997 og leverer teknologiprojekter med en forretningsorienteret tankegang og dyb teknisk ekspertise, herunder inden for IT-rådgivning, cloud-infrastruktur, cybersikkerhed, applikationsudvikling, projektlevering og forretningsarkitektur. Charter hjælper traditionelle virksomheder, offentlige institutioner, tjenesteudbydere og mellemstore kunder med implementering, netværksinfrastruktur og kundeorienterede applikationer – der leveres gennem en livscyklus-tilgang fra strategi til udførelse. "Vores mål hos Charter har altid været at fjerne kompleksiteten fra IT og hjælpe organisationer med at bevæge sig fremad med tillid," siger Kelly Michell, præsident for Charter. "Vores samarbejde med Andersen Consulting gør det muligt for os at bringe vores integrere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom